Unzyme Laboratories Announces Walk-In Trials Program for UPG Zeta
Revolutionary new approach to clinical trial accessibility launching April 2026 in Wrocław, Poland.
Media Center
Press Room
News, announcements, and resources for media professionals covering the human enhancement industry.
Press Releases
CogniShield MT Receives Commercial Approval in European Markets
Mental privacy protection device now available for civilian use across 18 countries.
UPG Zeta Groundbreaking Ceremony in Wrocław
Construction begins on Unzyme's largest and most advanced proving ground facility.
Unzyme Laboratories Opens UPG Epsilon in Helsinki
New facility expands pharmaceutical enhancement testing capabilities in the Nordic region.
HaemoFlow X Achieves FDA Approval for Specific Medical Conditions
Blood enhancement therapy cleared for treatment of chronic fatigue and altitude-related disorders.
Partnership Announced with NATO Enhancement Initiative
Multi-year agreement to develop advanced enhancement solutions for allied defense forces.
About Unzyme Laboratories
Unzyme Laboratories is a global leader in human enhancement technology, developing and commercializing advanced biotechnological solutions that optimize human performance. Founded in 2008 in Helsinki, Finland, the company operates research and testing facilities across Europe and serves clients in the healthcare, defense, and consumer markets. Unzyme's product portfolio includes neural interfaces, cardiovascular enhancers, pharmaceutical optimization systems, and cognitive protection devices. The company's mission is to liberate humanity from the constraints of biological evolution.
This boilerplate may be used without modification in press coverage.